Headache Treatments
Michael A. Rogawski, M.D., Ph.D.
  • Home
  • Search
  • Testing Routine Blood Migraine
  • Acute Migraine Treatments
  • Behavioral Therapy
  • Botox
  • Breastfeeding
  • Butterbur
  • Cannabinoids
  • Cerebral Vascular Anatomy
  • CGRP Antibodies and Gepants
  • Children and Adolescents
  • Chronic Pain / Back Pain
  • Cluster Headache Treatment
  • Contraception - Birth Control
  • Depression Screening PHQ-2 and PHQ-9
  • Deprescribing/ Withdrawing Medications
  • Devices
  • Emergency Department Treatment / Steroid Taper
  • Epilepsy/Seizure Drugs in Development
  • Exercise
  • HIT-6 Headache Impact Test
  • Headache Tracking
  • Headache Types
  • Hemiplegic Migraine
  • High and Low Pressure Headache
  • Hypertension Guidlines
  • Indomethacin Responsive Headaches
  • IV Infusion Protocols
  • Magnesium, Nutritional Supplements and Alternative
  • Medication Overuse Headache
  • Menopause - Menopausal Vasomotor Symptoms
  • Menstrual Migraine
  • MIDAS (Migraine Disability Assessment) and ASC-12
  • Migraine Mimics
  • Neck Pain; Spinal Anatomy & Dermtomes
  • Nerve Blocks
  • Nonpharmacological Measures
  • NSAID
  • Occipital Epilepsy
  • Publications
  • Posttraumatic Headache
  • Pregnancy
  • Preventative Migraine Treatments
  • Prodrome and Aura
  • Red Flag Symptoms
  • Sleep - Insomnia
  • SphenoCath
  • Sphenopalatine Ganglion Block
  • Status migrainosus
  • Tension Type Headache
  • Thunderclap Headache
  • Tinnitus
  • Triggers/Caffeine
  • Vestibular Migraine
  • Lawrence Robbins: Advanced Headache Therapy

Menopausal Vasomotor Symptoms


​​Antidepressants produced modest improvements in vasomotor symptoms.

Venlafaxine and low-dose oral estradiol equally effective in reducing hot flashes (50% vs 30% with placebo)
​
Reed SD, LaCroix AZ, Anderson GL, Ensrud KE, Caan B, Carpenter JS, Cohen L, Diem SJ, Freeman EW, Joffe H, Larson JC, McCurry SM, Mitchell CM, Newton KM, Sternfeld B, Guthrie KA. Lights on MsFLASH: a review of contributions. Menopause. 2020 Apr;27(4):473-484.

Veozah (fezolinetant) - NK3 Receptor Antagonist

Dose: 45 mg q day

​The neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) is FDA-approved for treatment of moderate to severe VMS. Blocking neurokinin B activity restores hypothalamic thermoregulatory control, reducing VMS. In clinical trials in women with moderate to severe VMS associated with menopause, reductions in the frequency and severity of VMS were statistically significantly greater with fezolinetant than with placebo.19,20 Fezolinetant can cause abdominal pain, diarrhea, insomnia, back pain, hot flushes, and hepatic transaminase elevations. Fezolinetant is contraindicated for use with a CYP1A2 inhibitor.

Transdermal Estrogen/Progestin Combinations

For menopausal vasomotor symptoms. Women with an intact uterus who take a systemic estrogen should also take a progestogen to reduce the risk of endometrial hyperplasia and adenocarcinoma. Progestin should not be used in women who have had uterus removed. Transdermal formulations are as effective as oral estrogens in reducing vasomotor symptoms and may be safer.
 
Climara Pro – Estradiol/levonorgestrel
Estradiol 0.045 mg + levonorgestrel 0.015 mg; per day; transdermal system.
Once per week.
 
CombiPatch – Estradiol/norethindrone
Estradiol 0.05 mg + norethindrone acetate 0.14 mg; per day; transdermal system.
Estradiol 0.05 mg + norethindrone acetate 0.25 mg; per day; transdermal system.
Twice per week.

Climara Pro and CombiPatch are in table below. Note that Climara Pro is once a week.

Picture

PROMETRIUM® (micronized progesterone for oral administration) Prevents Endometrial Hyperplasia

Picture
Picture